BridgeBio Pharma Other Share Holders Equity 2018-2024 | BBIO

BridgeBio Pharma other share holders equity from 2018 to 2024. Other share holders equity can be defined as field containing the sum of all current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
  • BridgeBio Pharma other share holders equity for the quarter ending June 30, 2024 was $M, a NAN% increase year-over-year.
  • BridgeBio Pharma other share holders equity for 2023 was $0B, a NAN% decline from 2022.
  • BridgeBio Pharma other share holders equity for 2022 was $0B, a NAN% decline from 2021.
  • BridgeBio Pharma other share holders equity for 2021 was $0B, a NAN% decline from 2020.
BridgeBio Pharma Annual Other Share Holders Equity
(Millions of US $)
2023 $
2022 $
2021 $
2020 $
2019 $
2018 $
2017 $0
BridgeBio Pharma Quarterly Other Share Holders Equity
(Millions of US $)
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30 $0
2019-03-31 $0
2018-12-31
2018-09-30 $0
2017-12-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $5.028B $0.009B
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.837B 6.73
Dr Reddy's Laboratories (RDY) India $13.111B 19.64
Bausch Health Cos (BHC) Canada $2.902B 2.19
Amphastar Pharmaceuticals (AMPH) United States $2.394B 13.40
Supernus Pharmaceuticals (SUPN) United States $1.753B 353.56
Taysha Gene Therapies (TSHA) United States $0.441B 71.67
Personalis (PSNL) United States $0.305B 0.00
Assembly Biosciences (ASMB) United States $0.123B 0.00
Acasti Pharma (ACST) Canada $0.027B 0.00
Sol-Gel Technologies (SLGL) Israel $0.020B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00